Related Experiment Video
Updated: Dec 10, 2025

Evaluation of the Storage Stability of Extracellular Vesicles
Published on: May 22, 2019
Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials
Micaela M ViÑa-Romero1, Ruth Ramos-Diaz2, Ivette Mourani-Padron2
1Hospital Pharmacy Service, University Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain.
Background/Aim:
L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the leftover is usually discarded. The aim of this study will be to analyse the stability of the reconstituted lyophilised ERW-ASNase.
Materials And Methods:
In the present study, we analysed the enzymatic stability of reconstituted ERW-ASNase after conservation in three different temperature conditions for 2 and 5 days.
Results:
Our results show that ERW-ASNase is stable at 4°C, -20°C and -80°C for up to 5 days, retaining 95% of the initial enzymatic activity in all three storage temperatures tested.
Conclusion:
It is feasible to reuse the remaining content of ERW-ASNase vial after reconstitution, which allows the optimization of the content of ERW-ASNase vials use and reduces the cost of this formulation usage, making it more accessible.
More Related Videos
Related Concept Videos
Drug Product Stability
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

